{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:47Z","timestamp":1793948447775,"version":"4.8.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81900639"],"award-info":[{"award-number":["81900639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shenzhen Second People\u2019s Hospital Clinical Research Fund of Guangdong Province High-level Hospital Construction Project","award":["20223357009"],"award-info":[{"award-number":["20223357009"]}]},{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["SZXK009"],"award-info":[{"award-number":["SZXK009"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"crossref","award":["SZSM202211013"],"award-info":[{"award-number":["SZSM202211013"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04086-3","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:51:52Z","timestamp":1742964712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Emerging role of Rituximab in adult minimal change disease: a narrative review of clinical evidence, biomarkers and future perspectives"],"prefix":"10.1186","volume":"26","author":[{"given":"Anni","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"4086_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0272-6386(87)80170-1","volume":"10","author":"JS Cameron","year":"1987","unstructured":"Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis. 1987;10:157\u201371.","journal-title":"Am J Kidney Dis"},{"key":"4086_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.03531006","volume":"2","author":"M Waldman","year":"2007","unstructured":"Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2:445\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4086_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, et al. Minimal change disease. Clin J Am Soc Nephrol. 2017;12:332\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4086_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","volume":"NEPHRUTIX","author":"A Boumediene","year":"2018","unstructured":"Boumediene A, Vachin P, Sendeyo K, et al. A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun. 2018;NEPHRUTIX:88: 91\u2013102.","journal-title":"J Autoimmun"},{"key":"4086_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts AJB, Keller KH, Lerner G, et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol. 2022;33:238\u201352.","journal-title":"J Am Soc Nephrol"},{"key":"4086_CR6","doi-asserted-by":"crossref","unstructured":"KDIGO. 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1\u2013s276.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"4086_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000486930","volume":"195","author":"Y Iwabuchi","year":"2018","unstructured":"Iwabuchi Y, Moriyama T, Itabashi M, et al. Rituximab as a therapeutic option for Steroid-Sensitive minimal change nephrotic syndrome in adults. Contrib Nephrol. 2018;195:12\u20139.","journal-title":"Contrib Nephrol"},{"key":"4086_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2215\/CJN.06180519","volume":"15","author":"NR Medjeral-Thomas","year":"2020","unstructured":"Medjeral-Thomas NR, Lawrence C, Condon M, et al. Controlled trial of tacrolimus and prednisolone monotherapy for adults with de Novo minimal change disease: A multicenter, randomized, controlled trial. Clin J Am Soc Nephrol. 2020;15:209\u201318. Randomized.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4086_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1681\/ASN.2016030342","volume":"28","author":"X Li","year":"2017","unstructured":"Li X, Liu Z, Wang L, et al. Tacrolimus monotherapy after intravenous Methylprednisolone in adults with minimal change nephrotic syndrome. J Am Soc Nephrol. 2017;28:1286\u201395.","journal-title":"J Am Soc Nephrol"},{"key":"4086_CR10","doi-asserted-by":"crossref","unstructured":"Ramachandran R, Kumar DAP, Nada R et al. Chronic nephrotoxicity limits successful use of Tacrolimus in the management of adult steroid-dependent minimal change disease. Nephrol (Carlton) 2015;20:384\u2013385.","DOI":"10.1111\/nep.12392"},{"key":"4086_CR11","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90:2188\u201395.","journal-title":"Blood"},{"key":"4086_CR12","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006;54:2970\u201382.","journal-title":"Arthritis Rheum"},{"key":"4086_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1681\/ASN.2008070786","volume":"21","author":"D Jayne","year":"2010","unstructured":"Jayne D. Role of rituximab therapy in glomerulonephritis. J Am Soc Nephrol. 2010;21:14\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"4086_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa2314471","volume":"391","author":"FE Hengel","year":"2024","unstructured":"Hengel FE, Dehde S, Lass\u00e9 M, et al. Autoantibodies targeting nephrin in podocytopathies. N Engl J Med. 2024;391:422\u201333.","journal-title":"N Engl J Med"},{"key":"4086_CR15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41581-024-00873-7","volume":"20","author":"MH Cui ZandZhao","year":"2024","unstructured":"Cui ZandZhao MH. Anti-nephrin autoantibodies: a paradigm shift in podocytopathies. Nat Rev Nephrol. 2024;20:639\u201340.","journal-title":"Nat Rev Nephrol"},{"key":"4086_CR16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.kint.2024.09.006","volume":"106","author":"V Raglianti","year":"2024","unstructured":"Raglianti V, Angelotti ML, Cirillo L, et al. Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants. Kidney Int. 2024;106:1124\u201334.","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"4086_CR17","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","volume":"13","author":"T Cerny","year":"2002","unstructured":"Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs. 2002;13(Suppl 2):S3\u201310.","journal-title":"Anticancer Drugs"},{"key":"4086_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrd2085","volume":"5","author":"JL Browning","year":"2006","unstructured":"Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;5:564\u201376.","journal-title":"Nat Rev Drug Discov"},{"key":"4086_CR19","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3:85ra46.","journal-title":"Sci Transl Med"},{"key":"4086_CR20","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2215\/CJN.11941115","volume":"11","author":"CY Chan","year":"2016","unstructured":"Chan CY, Liu ID, Resontoc LP, et al. T lymphocyte activation markers as predictors of responsiveness to rituximab among patients with FSGS. Clin J Am Soc Nephrol. 2016;11:1360\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4086_CR21","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, et al. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol. 2016;27:1811\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"4086_CR22","doi-asserted-by":"publisher","first-page":"205435811769866","DOI":"10.1177\/2054358117698667","volume":"4","author":"N Madanchi","year":"2017","unstructured":"Madanchi N, Bitzan MandTakano T. Rituximab in minimal change disease: mechanisms of action and hypotheses for future studies. Can J Kidney Health Dis. 2017;4:2054358117698667.","journal-title":"Can J Kidney Health Dis"},{"key":"4086_CR23","doi-asserted-by":"publisher","first-page":"28799","DOI":"10.18632\/oncotarget.25612","volume":"9","author":"R Fenoglio","year":"2018","unstructured":"Fenoglio R, Sciascia S, Beltrame G, et al. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget. 2018;9:28799\u2013804.","journal-title":"Oncotarget"},{"key":"4086_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ekir.2023.02.1070","volume":"8","author":"N Guan","year":"2023","unstructured":"Guan N, Zhang M, Zhang M, et al. Rituximab as initial therapy in adult patients with minimal change disease. Kidney Int Rep. 2023;8:1102\u20134.","journal-title":"Kidney Int Rep"},{"key":"4086_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/ndt\/gfae012","volume":"39","author":"R Xu","year":"2024","unstructured":"Xu R, Hu H, Xu H, et al. Initial rituximab monotherapy for adult indiopathic nephrotic syndrome with minimal change lesion pattern. Nephrol Dial Transpl. 2024;39:893\u20135.","journal-title":"Nephrol Dial Transpl"},{"key":"4086_CR26","doi-asserted-by":"publisher","first-page":"1403562","DOI":"10.3389\/fphar.2024.1403562","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Yan P, Zhang L, et al. The efficacy and safety of half-dose glucocorticoids combined with rituximab versus high-dose glucocorticoids for initial treatment of minimal change disease: a single-center experience. Front Pharmacol. 2024;15:1403562.","journal-title":"Front Pharmacol"},{"key":"4086_CR27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ndt\/gft366","volume":"29","author":"S Fervenza FCandSethi","year":"2014","unstructured":"Fervenza FCandSethi S. Frequent-relapsing, steroid-dependent minimal change disease: is rituximab the answer? Nephrol Dial Transpl. 2014;29:722\u20137.","journal-title":"Nephrol Dial Transpl"},{"key":"4086_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1365-4632.2009.04322.x","volume":"49","author":"VP Moghadam-Kia SandWerth","year":"2010","unstructured":"Moghadam-Kia SandWerth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49:239\u201348.","journal-title":"Int J Dermatol"},{"key":"4086_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/ndt\/gfae025","volume":"39","author":"S Mirioglu","year":"2024","unstructured":"Mirioglu S, Daniel-Fischer L, Berke I, et al. Management of adult patients with podocytopathies: an update from the ERA immunonephrology working group. Nephrol Dial Transpl. 2024;39:569\u201380.","journal-title":"Nephrol Dial Transpl"},{"key":"4086_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00467-006-0427-5","volume":"22","author":"GC Smith","year":"2007","unstructured":"Smith GC. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol. 2007;22:893\u20138.","journal-title":"Pediatr Nephrol"},{"key":"4086_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc AL, Macher MA, Loirat C, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109\u201315.","journal-title":"Pediatr Nephrol"},{"key":"4086_CR32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","volume":"28","author":"T Takei","year":"2013","unstructured":"Takei T, Itabashi M, Moriyama T, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transpl. 2013;28:1225\u201332.","journal-title":"Nephrol Dial Transpl"},{"key":"4086_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12882-023-03092-7","volume":"24","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhao H, Li X, et al. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse. BMC Nephrol. 2023;24:112.","journal-title":"BMC Nephrol"},{"key":"4086_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","volume":"21","author":"P Hansrivijit","year":"2020","unstructured":"Hansrivijit P, Cheungpasitporn W, Thongprayoon C, et al. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol. 2020;21:134.","journal-title":"BMC Nephrol"},{"key":"4086_CR35","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","volume":"14","author":"C Xue","year":"2021","unstructured":"Xue C, Yang B, Xu J, et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clin Kidney J. 2021;14:1042\u201354.","journal-title":"Clin Kidney J"},{"key":"4086_CR36","doi-asserted-by":"publisher","first-page":"2428330","DOI":"10.1080\/0886022X.2024.2428330","volume":"46","author":"A Yimamuyushan","year":"2024","unstructured":"Yimamuyushan A, Li Y, Jiao W, et al. Combination of rituximab and low-dose glucocorticoids for idiopathic refractory nephrotic syndrome with MCD\/FSGS: a single-center prospective cohort study. Ren Fail. 2024;46:2428330.","journal-title":"Ren Fail"},{"key":"4086_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12882-021-02437-4","volume":"22","author":"D Liu","year":"2021","unstructured":"Liu D, Zhou Z, Wang M, et al. Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease. BMC Nephrol. 2021;22:242.","journal-title":"BMC Nephrol"},{"key":"4086_CR38","doi-asserted-by":"publisher","first-page":"2237124","DOI":"10.1080\/0886022X.2023.2237124","volume":"45","author":"X Ma","year":"2023","unstructured":"Ma X, Fang L, Sheng L, et al. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study. Ren Fail. 2023;45:2237124.","journal-title":"Ren Fail"},{"key":"4086_CR39","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ki.2012.444","volume":"83","author":"H Munyentwali","year":"2013","unstructured":"Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83:511\u20136.","journal-title":"Kidney Int"},{"key":"4086_CR40","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","volume":"29","author":"J Guitard","year":"2014","unstructured":"Guitard J, Hebral AL, Fakhouri F, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transpl. 2014;29:2084\u201391.","journal-title":"Nephrol Dial Transpl"},{"key":"4086_CR41","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"4086_CR42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40259-017-0221-x","volume":"31","author":"I DaSilva","year":"2017","unstructured":"DaSilva I, Huerta A, Quintana L, et al. Rituximab for Steroid-Dependent or frequently relapsing idiopathic nephrotic syndrome in adults: A retrospective, multicenter study in Spain. BioDrugs. 2017;31:239\u201349.","journal-title":"BioDrugs"},{"key":"4086_CR43","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/ndt\/gfaa133","volume":"36","author":"C Heybeli","year":"2021","unstructured":"Heybeli C, Erickson SB, Fervenza FC, et al. Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease. Nephrol Dial Transpl. 2021;36:1821\u20137.","journal-title":"Nephrol Dial Transpl"},{"key":"4086_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000535010","volume":"55","author":"L Lan","year":"2024","unstructured":"Lan L, Lin Y, Yu B, et al. Efficacy of rituximab for minimal change disease and focal segmental glomerulosclerosis with frequently relapsing or Steroid-Dependent nephrotic syndrome in adults: A Chinese multicenter retrospective study. Am J Nephrol. 2024;55:25\u201336.","journal-title":"Am J Nephrol"},{"key":"4086_CR45","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1007\/s00467-006-0228-x","volume":"21","author":"RD Gilbert","year":"2006","unstructured":"Gilbert RD, Hulse EandRigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol. 2006;21:1698\u2013700.","journal-title":"Pediatr Nephrol"},{"key":"4086_CR46","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transpl. 2012;27:1910\u20135.","journal-title":"Nephrol Dial Transpl"},{"key":"4086_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/01.TP.0000112934.12622.2B","volume":"77","author":"CA Vieira","year":"2004","unstructured":"Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77:542\u20138.","journal-title":"Transplantation"},{"key":"4086_CR48","doi-asserted-by":"publisher","first-page":"1024068","DOI":"10.3389\/fimmu.2022.1024068","volume":"13","author":"JM Hartinger","year":"2022","unstructured":"Hartinger JM, Kratky V, Hruskova Z, et al. Implications of rituximab Pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Front Immunol. 2022;13:1024068.","journal-title":"Front Immunol"},{"key":"4086_CR49","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.2147\/DDDT.S302257","volume":"15","author":"L Lin","year":"2021","unstructured":"Lin L, Wang W, Wu Y, et al. Consolidation treatment and Long-Term prognosis of rituximab in minimal change disease and focal segmental glomerular sclerosis. Drug Des Devel Ther. 2021;15:1945\u201353.","journal-title":"Drug Des Devel Ther"},{"key":"4086_CR50","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1038\/s41598-023-32576-7","volume":"13","author":"T Osterholt","year":"2023","unstructured":"Osterholt T, Todorova P, K\u00fchne L, et al. Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS. Sci Rep. 2023;13:6980.","journal-title":"Sci Rep"},{"key":"4086_CR51","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138.","journal-title":"Pediatr Nephrol"},{"key":"4086_CR52","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc AL, Baudouin V, Kwon T, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2013follow-up after CD19 recovery. Nephrol Dial Transpl. 2012;27:1083\u20139.","journal-title":"Nephrol Dial Transpl"},{"key":"4086_CR53","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269\u201379.","journal-title":"Pediatr Nephrol"},{"key":"4086_CR54","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.2169\/internalmedicine.2236-18","volume":"58","author":"H Nishiwaki","year":"2019","unstructured":"Nishiwaki H, Oikawa M, Kajitani H, et al. Disseminated intravascular Coagulation-like reaction after rituximab infusion in a patient with nephrotic syndrome. Intern Med. 2019;58:2057\u201361.","journal-title":"Intern Med"},{"key":"4086_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish RandFalck-Ytter YT. American gastroenterological association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221\u2013e244223.","journal-title":"Gastroenterology"},{"key":"4086_CR56","doi-asserted-by":"crossref","unstructured":"EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04086-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04086-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04086-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T05:57:21Z","timestamp":1743314241000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04086-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4086"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04086-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}